Core Viewpoint - The Hong Kong innovative drug sector continues to adjust, with the core Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing fluctuations below the surface, nearing its lowest point since July. However, there is a surge in buying interest as funds have entered the market significantly in recent days, indicating active buying momentum [1][6]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a net subscription of over 56 million yuan in the last two days, totaling over 113 million yuan [1][6]. - Leading stocks in the sector have shown a trend of more declines than gains, with companies like Kangfang Biotech and China Biopharmaceutical dropping over 2%, while CSPC Pharmaceutical rose over 2% [3][8]. Group 2: Industry Developments - Significant progress has been made in the negotiation of innovative drugs within the national medical insurance framework, with multiple products and new indications successfully included in the national medical insurance catalog. Companies like Innovent Biologics, Kangfang Biotech, and Kelun-Biotech have high negotiation success rates, which helps improve drug accessibility [3][8]. - The commercial insurance catalog is becoming an important incremental market, promoting the commercialization of innovative drugs. The overall industry is witnessing accelerated R&D, expansion of indications, and internationalization [3][8]. Group 3: Future Outlook - Innovative drugs are expected to accelerate their market penetration with the support of medical insurance, particularly in high-incidence areas with unmet clinical needs such as tumors and autoimmune diseases [3][8]. - The outbound model is continuously upgrading, enhancing the global competitiveness of Chinese innovative drug pipelines. New technologies like bispecific antibodies and targeted drugs are driving product differentiation [3][8]. - Policies continue to encourage the development of innovative drugs, providing long-term growth momentum for the industry [3][8]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the largest in its category, with a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [4][12]. - The index tracked by the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the index weight, indicating strong leadership in the innovative drug sector [4][11]. - The ETF is designed to be pure and comprehensive, focusing solely on innovative drug R&D companies, and it effectively controls risks associated with less liquid constituent stocks [4][10].

每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 华宝证券指出，港股市场迎来企稳修复，整体来看市场或正处于情绪回暖、风格切换阶段，权益市 场重返震荡上行通道。展望后市，随着春季行情临近，市场情绪有望回升，建议关注高景气方向的布局 机会。 港股科技ETF（513020）跟踪的是港股通科技指数（931573），覆盖【互联网+创新药+新能源车】 等港股核心资产，集中体现多元化科技产业特征与港股市场核心科技企业的整体表现。 港股通科技指数相比恒生科技指数超配新能源车、创新药等行业，从业绩表现来看，从2014年底基 日开始至2025年10月底，港股通科技指数累计收益256.46%，相对恒生科技指数（96.94%）超额近 160%，长期跑赢恒生科技指数、沪港深互联网指数、恒生互联网科技业指数、恒生医疗保健指数等同 类指数。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌 ...

Core Insights - The Hong Kong innovative drug sector is gaining market attention despite an overall market downturn, driven by several key developments [1][3][4] Group 1: Market Developments - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" on December 7, 2025, opens a "second payment channel" for high-value innovative drugs, injecting new momentum into the innovative drug industry [1][3] - The launch of the Chinese drug price registration system on December 2, 2025, aims to establish a global pricing system, potentially benefiting Chinese innovative drugs in international markets and attracting high-quality foreign drugs [1][3] - An announcement on December 9, 2025, from an innovative drug company regarding a $150 million upfront payment and up to $350 million in milestone payments for a business development deal indicates ongoing progress in the internationalization of Chinese innovative drugs [1][3] Group 2: Fund Performance - The Hang Seng Innovative Drug ETF (520500) has seen a significant inflow of funds, accumulating 154 million yuan over two trading days (December 8-9, 2025), with a record net inflow of 123 million yuan on December 9, 2025 [2][4] - Trading volume for the ETF has increased, with recorded transaction amounts of 680 million yuan and 780 million yuan over the last two days, compared to an average daily trading volume of 453 million yuan in the first five days of December [2][4] - As of December 9, 2025, the ETF's shares reached 1.203 billion, marking a historical high since its inception on December 16, 2024, with a total asset size of 2.031 billion yuan [2][4] Group 3: Index Composition - The Hang Seng Innovative Drug Index, which the ETF closely tracks, includes companies involved in the research, development, and production of innovative drugs, emphasizing firms with strong R&D capabilities [2][4] - The top five constituents of the index as of December 9, 2025, are Kangfang Biotech, China National Pharmaceutical Group, BeiGene, Innovent Biologics, and Kelun-Biotech [2][4] Group 4: Investment Outlook - The innovative drug sector in Hong Kong has experienced a notable correction since September 2025, but favorable policy and industry developments, along with expectations of U.S. Federal Reserve interest rate cuts and liquidity easing, suggest a potential investment window [2][4] - The Hang Seng Innovative Drug ETF (520500) is characterized by its large scale, favorable liquidity, and support for T+0 trading, making it an efficient tool for investors looking to capitalize on opportunities in the Hong Kong innovative drug sector [2][4]

Market Overview - After regaining the 3900-point level, the A-share market has returned to a phase of low-volume consolidation, with mixed performances across indices. The ChiNext Index continues to show upward momentum, while the Shanghai Composite Index and the Sci-Tech 50 Index have experienced slight pullbacks. Overall trading volume has decreased compared to Monday, reflecting a decline in investor enthusiasm as the year-end approaches, leading to a general trend of low-volume fluctuations [1] Future Outlook - As the year-end approaches, a cautious market sentiment prevails, with fluctuations around the 4000-point level potentially preparing the market for a new upward phase. The market has established conditions for further upward expansion following a period of sideways movement since October. A recovery in the supply-demand situation for the manufacturing sector in 2026 is likely, which could lead to a significant rebound in the earnings growth of A-share listed companies. Key focus areas for November include the impact of the 14th Five-Year Plan on industries, event-driven dynamics in the technology sector, and price increases driven by anti-involution trends, which are expected to catalyze multiple sectors and support a continued upward trend in the market [1] Sector Highlights - In December, sectors benefiting from dividends and price increases are expected to outperform, with short-term attention on banking, public utilities, coal, and non-ferrous metals. Technology will remain a key focus in 2026, with particular attention on AI, lithium batteries, military industry, and robotics. Specific areas of interest include: 1. The established trend in AI hardware, with a continued increase in token usage for major AI models, indicating a peak in AI applications by 2026, presenting opportunities for high growth in AI hardware and the transition from quantitative to qualitative changes in AI applications [2] 2. The trend of robot localization and integration into daily life is expected to continue into 2026, with robot products expanding from humanoid robots to quadrupedal and functional robots, creating recurring opportunities in sensors, controllers, and dexterous hands [2] 3. The trend towards semiconductor localization remains strong, with a focus on semiconductor equipment, wafer manufacturing, semiconductor materials, and IC design [2] 4. The military sector is expected to see a continued recovery in orders by 2026, with many sub-sectors such as ground equipment, aviation equipment, and military electronics showing signs of bottoming out as Q3 report declines narrow [2] 5. The innovative drug sector is entering a recovery phase after nearly four years of adjustment, with positive net profit growth for four consecutive quarters since Q3 2024, and an anticipated turning point in fundamentals by 2025, continuing an upward trend into 2026 [2]

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector is experiencing a buying surge as investors seek to capitalize on recent price adjustments, with significant net inflows into the Hong Kong Stock Connect Innovative Drug ETF (520880) [1][9]. Group 1: Market Activity - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw over 56 million yuan in net subscriptions over two consecutive days, marking a near one-month high in daily inflow, totaling over 113 million yuan [1][9]. - The index for the ETF has experienced a decline of over 18% since early September, indicating a substantial adjustment period that has released prior high-level risks [3][11]. Group 2: Industry Outlook - Continuous policy support for the pharmaceutical industry's innovation is evident, with the recent release of the 2025 National Medical Insurance Drug List, which added 114 new drugs, including 50 innovative drugs, achieving a historical success rate of 88% [5][13]. - The dual implementation of the medical insurance and commercial insurance drug lists is expected to provide a more stable policy outlook for innovative drugs, benefiting related companies [5][13]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is characterized by three unique advantages: it exclusively covers innovative drug companies, has a significant concentration of leading firms with over 72% weight in the top ten stocks, and employs measures to control risks associated with less liquid stocks [5][6][13]. - As of November 30, the ETF had a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan, making it the largest and most liquid ETF tracking the same index [7][14].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry, indicating an expected return that is stronger than the market benchmark by over 5% [5]. Core Insights - The National Medical Insurance Administration is strongly encouraging the high-quality development of innovative drugs, with clear policies supporting the payment side for innovative drugs. Domestic leading innovative drug companies are entering a commercial realization phase [3][7]. - The 2025 National Medical Insurance Drug List includes 127 products, with 114 successfully added, of which 50 are innovative drugs, marking a historical high. The overall negotiation success rate reached 90%, the highest in nearly seven years [7]. - The report highlights that the domestic innovative drug market is becoming increasingly concentrated, with leading companies like Heng Rui and Xin Da Biotech significantly benefiting from the new insurance policies [7]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Heng Rui Pharmaceutical (600276, Buy), Ke Lun Pharmaceutical (002422, Buy), Xin Li Tai (002294, Hold), Ao Sai Kang (002755, Buy), Jing Xin Pharmaceutical (002020, Buy), and others [3]. Market Dynamics - The report notes that the introduction of the commercial insurance directory marks the beginning of a "new golden decade" for Chinese innovative drugs, with a focus on high clinical efficacy and value innovation [7]. - The report emphasizes that the competition in the GLP-1 market remains clear, with the entry of new drugs not significantly altering the competitive landscape for existing treatments [7].

来源：市场资讯 机构还在指望"跨年行情"，但也指出"基本面未明显好转"，行业角度还是则还是聚焦景气行业，等着低吸，这和我们态度差不多。 最遭心的，还是港股。 有些事情不能谈太多，但这两天外资砸盘砸得来劲了。一个就是咱们昨天早报谈的"跨周期调节"，降低了外资对放大招的预期，另外一个H200进口利空 国产替代的情绪。 很多朋友难受，我们这边能做也是陪伴，不但恒生科技继续定投，加码港股通科技30的定投。年初和几个最爱骂A股的怄气：定投中证A500证明今年大不 相同，最终胜利了，现在重新用港股科技做下一场约定！ （来源：木鱼ETF） -阿里已成立千问C端事业群，首要目标是将千问打造成为一款超级APP 昨日预期行情会比较磨，最终盘面差不多。只要外资不带节奏，A股就需要持续的利好供给来炒作人气。周二就最终走了个普跌，也就是CPO抱团突破边 际有些赚钱效应。 而对于阿里巴巴来说，现在也开始了一场豪赌，就是要把千问打造成超级APP，淘宝之后的下一个。而且，近期豆包助手的启发相当大。至于信不信，就 是要押注了。消费层面大势依然下行，所以不在其他赛道形成突破，就是困局。 -哈塞特：美联储有大量降息空间 不止25个基点； -美联储 ...

Core Viewpoint - The Hong Kong stock market for innovative drugs continues to decline, with the Hang Seng Index falling below the six-month moving average, indicating ongoing adjustments in the sector [1][3]. Market Performance - On December 9, the Hong Kong innovative drug ETF (520880) experienced a decline of 1.99%, marking two consecutive days of losses, with a trading volume of 283 million yuan [1]. - Major stocks within the ETF saw significant declines, including Kangfang Biotech down 4%, Sanofi Biotech down 3.63%, and Innovent Biologics down 1.4% [1]. Investment Opportunities - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets, as the index has retraced over 18% since early September, indicating a sufficient adjustment and risk release [3]. - There are positive signals in the funding landscape, with over 56 million yuan net subscriptions for the innovative drug ETF on the previous day, the highest in nearly a month, indicating strong buying interest [4]. Policy Developments - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [5]. Business Development - Kelun-Biotech has granted exclusive rights to Crescent for the development of ADC drug SKB105 outside Greater China, along with exclusive rights for CR-001 bispecific antibody in Greater China, which includes an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [6]. - Analysts recommend focusing on innovative drug companies with rich pipeline layouts, high potential single products, and leading technology platforms [6]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten holdings accounting for over 72% of the index, showcasing the strength of the innovative drug sector [7]. - The ETF has a total market value of 2.142 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 458 million yuan since its inception [7].

Group 1 - The pharmaceutical sector continues to adjust, with various indices such as the Hang Seng Innovative Drug Index and the CSI Hong Kong Pharmaceutical and Health Comprehensive Index declining by 1.2% [1] - Despite the downturn, there is a significant capital inflow, with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of over 80 million units throughout the day [1] - The fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the persistent demand for pharmaceuticals and the increasing number of unmet needs, alongside continuous R&D investments by pharmaceutical companies [1] Group 2 - China has become a significant player in global innovative drug research and development, with overseas licensing activity continuing to rise year after year [1] - The pharmaceutical industry is entering a revenue era driven by innovation [1]

专题：2025中国企业竞争力年会 他谈到，科技壁垒高的中小企业可通过科创板、北交所上市，从二级市场获取发展资金。这一体系的成 效已充分显现，今年以来创新药、算力、机器人等新质生产力相关板块涨幅显著，既契合当前经济发展 重点，也反映出市场对这类企业成长潜力的认可。 陈雳强调，新质生产力的发展是一项系统工程，离不开宏观经济导向、产业布局规划、链主龙头企业引 领与区域协同发展的多方支撑。在百年未有之大变局与外部环境高度不确定的背景下，我国需练好内 功，推动国产自立与科技突破，而资本市场通过聚焦金融 "五篇大文章" 与新质生产力，进一步强化资 金保障，既能解决企业发展中的资金难题，又能助力破解国家与行业发展的关键问题，最终实现多方共 赢。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李思阳 专题：2025中国企业竞争力年会 "2025中国企业竞争力年会"于12月9日至10日在北京举行。川财证券首席经济学家、研究所所长陈雳指 出，资本市场对实体经济的服务作用不言而喻，其中一级市场投行业务是直接融资的核心抓手。 当前，投行在 ...